4.7 Article

Low Prevalence of High-Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study

期刊

CHEST
卷 150, 期 5, 页码 1015-1022

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.chest.2016.04.019

关键词

bronchoscopy; dysplasia; lung cancer; screening

资金

  1. Terry Fox Research Institute
  2. Canadian Partnership Against Cancer
  3. Princess Margaret Cancer Foundation Lusi Wong Fund

向作者/读者索取更多资源

BACKGROUND: Lung cancer screening with low-dose CT (LDCT) scan has been demonstrated to reduce lung cancer mortality. Preliminary reports suggested that up to 20% of lung cancers may be CT scan occult but detectable by autofluorescence bronchoscopy (AFB). We evaluated the prevalence of CT scan occult, invasive, and high-grade preinvasive lesions in high-risk participants undergoing screening for lung cancer. METHODS: The first 1,300 participants from seven centers in the Pan-Canadian Early Detection of Lung Cancer Study who had >= 2% lung cancer risk over 5 years were invited to have an AFB in addition to a LDCT scan. We determined the prevalence of CT scan and AFB abnormalities and analyzed the association between selected predictor variables and preinvasive lesions plus invasive cancer. RESULTS: A total of 776 endobronchial biopsies were performed in 333 of 1,300 (25.6%) participants. Dysplastic or higher-grade lesions were detected in 5.3% of the participants (n - 68; mild dysplasia: n - 36, moderate dysplasia: n - 25, severe dysplasia: n - 3, carcinoma in situ [CIS]: n - 1, and carcinoma: n - 4). Only one typical carcinoid tumor and one CIS lesion were detected by AFB alone, for a rate of CT scan occult cancer of 0.15% (95% CI, 0.0%-0.6%). Fifty-six prevalence lung cancers were detected by LDCT scan (4.3%). The only independent risk factors for finding of dysplasia or CIS on AFB were smoking duration (OR, 1.05; 95% CI, 1.02-1.07) and FEV1 percent predicted (OR, 0.99; 95% CI, 0.98-0.99). CONCLUSIONS: The addition of AFB to LDCT scan in a high lung cancer risk cohort detected too few CT occult cancers (0.15%) to justify its incorporation into a lung cancer screening program.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Respiratory System

Long-term modulation of airway remodelling in severe asthma following bronchial thermoplasty

Nicholas Jendzjowsky, Austin Laing, Michelle Malig, John Matyas, Elaine de Heuvel, Curtis Dumonceaux, Elaine Dumoulin, Alain Tremblay, Richard Leigh, Alex Chee, Margaret M. Kelly

Summary: Bronchial thermoplasty primarily affects airway smooth muscle and nerves, with effects still present at 12 months post-treatment.

EUROPEAN RESPIRATORY JOURNAL (2022)

Article Medicine, General & Internal

Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial

Karim Ali, Tanweer Azher, Mahin Baqi, Alexandra Binnie, Sergio Borgia, Francois M. Carrier, Yiorgos Alexandros Cavayas, Nicolas Chagnon, Matthew P. Cheng, John Conly, Cecilia Costiniuk, Peter Daley, Nick Daneman, Josh Douglas, Catarina Downey, Erick Duan, Emmanuelle Duceppe, Madeleine Durand, Shane English, George Farjou, Evradiki Fera, Patricia Fontela, Rob Fowler, Michael Fralick, Anna Geagea, Jennifer Grant, Luke B. Harrison, Thomas Havey, Holly Hoang, Lauren E. Kelly, Yoav Keynan, Kosar Khwaja, Gail Klein, Marina Klein, Christophe Kolan, Nadine Kronfli, Francois Lamontagne, Michael Lau, Todd C. Lee, Nelson Lee, Rachel Lim, Sarah Longo, Alexandra Lostun, Erika MacIntyre, Isabelle Malhame, Kathryn Mangoff, Marlee McGuinty, Sonya Mergler, Matthew Munan, Srinivas Murthy, Conar O'Neil, Daniel Ovakim, Jesse Papenburg, Ken Kuljit S. Parhar, Seema Nair Parvathy, Chandni Patel, Santiago Perez-Patrigeon, Ruxandra Pinto, Subitha Rajakumaran, Asgar Rishu, Malaika Roba-Oshin, Moira Rushton, Mariam Saleem, Marina Salvadori, Kim Scherr, Kevin Schwartz, Makeda Semret, Michael Silverman, Ameeta Singh, Wendy Sligl, Stephanie Smith, Ranjani Somayaji, Darrell H. S. Tan, Siobhan Tobin, Meaghan Todd, Tuong-Vi Tran, Alain Tremblay, Jennifer Tsang, Alexis Turgeon, Erik Vakil, Jason Weatherald, Cedric Yansouni, Ryan Zarychanski

Summary: This Canadian study explores the effectiveness of remdesivir as a treatment for COVID-19. The results show that remdesivir has a modest but significant impact on important outcomes for patients and healthcare systems, such as the need for mechanical ventilation.

CANADIAN MEDICAL ASSOCIATION JOURNAL (2022)

Editorial Material Oncology

Introduction to 2021 WHO Classification of Thoracic Tumors

Ming-Sound Tsao, Andrew G. Nicholson, Joseph J. Maleszewski, Alexander Marx, William D. Travis

JOURNAL OF THORACIC ONCOLOGY (2022)

Article Oncology

Economic impact of using risk models for eligibility selection to the International lung screening Trial

Sonya Cressman, Marianne F. Weber, Preston J. Ngo, Stephen Wade, Silvia Behar Harpaz, Michael Caruana, Alain Tremblay, Renee Manser, Emily Stone, Sukhinder Atkar-Khattra, Deme Karikios, Cheryl Ho, Aleisha Fernandes, Jing Yi Weng, Annette McWilliams, Renelle Myers, John Mayo, John Yee, Ren Yuan, Henry M. Marshall, Kwun M. Fong, Stephen Lam, Karen Canfell, Martin C. Tammemagi

Summary: Using risk models as eligibility criteria for lung screening can reduce race and sex-based disparities. In this study, the economic impact of using the PLCOm2012 risk model or the USPSTF-2013 categorical age-smoking history-based criteria was compared. The PLCOm2012 model resulted in cost savings, increased Quality-Adjusted Life Years (QALYs), and mitigated socioeconomic and sex-based disparities in access to screening.

LUNG CANCER (2023)

Article Medicine, General & Internal

Risk Model-Based Lung Cancer Screening A Cost-Effectiveness Analysis

Iakovos Toumazis, Pianpian Cao, Koen de Nijs, Mehrad Bastani, Vidit Munshi, Mehdi Hemmati, Kevin ten Haaf, Jihyoun Jeon, Martin Tammemagi, G. Scott Gazelle, Eric J. Feuer, Chung Yin Kong, Rafael Meza, Harry J. de Koning, Sylvia K. Plevritis, Summer S. S. Han

Summary: In their 2021 update, the USPSTF emphasized the need for further research on the benefits and harms of risk model-based lung cancer screening strategies. This comparative modeling analysis found that risk model-based screening strategies were more cost-effective than the USPSTF recommendation, with a 6-year risk threshold of 1.2% or greater being the most cost-effective.

ANNALS OF INTERNAL MEDICINE (2023)

Article Oncology

Probability of lung cancer in a population excluded from screening due to low PLCOM2012 risk

Paul MacEachern, Matthew T. Warkentin, Darren R. Brenner, Eric L. R. Bedard, Alain Tremblay

Summary: This study examined lung cancer rates in individuals who underwent computed tomography (CT) screening and those who did not. The findings suggest that using personalized risk as the criterion for screening eligibility is unlikely to miss many cases of lung cancer.

CANCER EPIDEMIOLOGY (2023)

Review Critical Care Medicine

The Global Burden of Pleural Diseases

Erik Vakil, Niloofar Taghizadeh, Alain Tremblay

Summary: Pleural diseases encompass pneumothorax and pleural effusion, causing pain, breathlessness, cough, and diminished quality of life. Disease burden varies regionally due to factors such as smoking, pneumonia, tuberculosis, asbestos, cancer, and organ failure. High-income countries have a higher disease burden due to better data availability, while lower-income countries likely have underestimated burdens. In the United States, there were 42,215 treat-and-discharge visits and 361,270 hospitalizations for pleural diseases in 2016, resulting in a national cost of $10.1 billion.

SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

Article Respiratory System

Prevalence and outcomes of interstitial lung abnormalities in a Canadian lung cancer screening trial

Katelyn Stuart, Marwa Ahmad, Stacey D. Lok, Ashley-Mae Gillson, Eric L. R. Bedard, Alain Tremblay, Kerri A. Johannson

Summary: This study investigates the prevalence and outcomes of ILA in a Canadian lung cancer screening cohort. The study finds that ILA is present in 3.7% of the cohort, with most cases being subpleural fibrotic abnormalities. The study suggests standardized reporting and follow-up for ILA in lung cancer screening programs.

CANADIAN JOURNAL OF RESPIRATORY CRITICAL CARE AND SLEEP MEDICINE (2023)

Article Oncology

Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer screening eligibility criteria in individuals with lung cancer in South Dakota self-reporting as Indigenous and non-Indigenous

Martin Carl Tammemagi, Kristin Cina, Andrea K. Borondy Kitts, David Koop, Mark A. Petereit, Michele Sargent, Daniel G. Petereit

Summary: This study compared screening eligibility for lung cancer in South Dakota using different criteria and models. It found no disparities in eligibility for individuals self-reporting as Indigenous. The PLCOm2012 risk-prediction model showed higher sensitivity in identifying lung cancer cases for screening compared to the US Preventive Services Task Force (USPSTF) criteria. Screening individuals younger than 50 years did not seem necessary in this population.

CANCER (2023)

Editorial Material Oncology

Time to quit using quit time as a lung cancer screening eligibility criterion

Martin Carl Tammemagi

Summary: Multiple lines of reasoning and evidence, including the study by Meza and colleagues, suggest that the use of the <= 15 quit-years rule for lung cancer screening eligibility should be abandoned.

CANCER (2023)

Meeting Abstract Respiratory System

Economics, equity and eligibility: Using risk models versus age-smoke history categorical criteria for selection to the international lung screening trial

Sonya Cressman, Marianne Weber, Preston Ngo, Alain Tremblay, Stephen Wade, Renee Manser, Emily Stone, Sukhinder Atkar-Khattra, Deme Karikios, Cheryl Ho, Silvia Behar Harpaz, Michael Caruana, Aleisha Fernandes, Jing Yi Weng, Annette McWilliams, Renelle Meyers, John Mayo, John Yee, Ren Yuan, Henry Marshall, Kwun Fong, Stephen Lam, Karen Canfell, Martin Tammemagi

RESPIROLOGY (2023)

Review Oncology

Direct GDP-KRASG12C inhibitors and mechanisms of resistance: the tip of the iceberg

Joshua C. Rosen, Adrian Sacher, Ming-Sound Tsao

Summary: KRAS(G12C) inhibitors have shown promising results in clinical trials with overall response rates ranging between 32% and 46%, and have been granted FDA approvals as second-line or later monotherapies. However, rapid tumor resistance complicates their use as a monotherapy.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2023)

Article Respiratory System

Silver Nitrate-coated versus Standard Indwelling Pleural Catheter for Malignant Effusions The SWIFT Randomized Trial

Joseph B. Shrager, Rahul Bhatnagar, Christine T. Kearney, Nathan P. Retzlaff, Evan Cohen, Andrew E. Stanton, Colleen Keyes, Momen M. Wahidi, Colin Gillespie, Najib Rahman, Anthony L. Kerry, David Feller-Kopman, Daniel Nader, Jason Akulian, Alex Chen, Mark Berry, Adnan Majid, Chakravarthy Reddy, Alain Tremblay, Nick A. Maskell

Summary: This study compared the efficacy of a novel silver nitrate-eluting indwelling pleural catheter with a standard, uncoated catheter. The results showed that the novel catheter did not improve pleurodesis efficacy and does not support its wider use.

ANNALS OF THE AMERICAN THORACIC SOCIETY (2022)

Article Oncology

Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer

Shelley Kuang, Andrea S. Fung, Kirstin A. Perdrizet, Kaitlin Chen, Janice J. N. Li, Lisa W. Le, Michael Cabanero, Ola Abu Al Karsaneh, Ming S. Tsao, Josh Morganstein, Laura Ranich, Adam C. Smith, Cuihong Wei, Carol Cheung, Frances A. Shepherd, Geoffrey Liu, Penelope Bradbury, Prodipto Pal, Joerg Schwock, Adrian G. Sacher, Jennifer H. Law, Tracy L. Stockley, Natasha B. Leighl

Summary: In NSCLC patients, reflex testing using NGS panels can identify actionable genetic variants in the majority of cases with minimal increase in testing cost. Implementation of NGS panels is essential for the treatment of NSCLC patients as treatment paradigms continue to evolve.

CURRENT ONCOLOGY (2022)

Meeting Abstract Medicine, Research & Experimental

Reproducibility in Assessment of Invasion in Lung Adenocarcinoma with Lepidic Component: An Interobserver Concordance Study with Cytokeratin 7 Stain

Ellen Yang, Najd Alshamlan, Jessica Weiss, Michael Cabanero, Ming Tsao

LABORATORY INVESTIGATION (2022)

暂无数据